125 related articles for article (PubMed ID: 32819122)
1. The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
Yang H; He L; Zhang Y; Li Y; Huang X; Li Y; Lou Y; Wang L
Ann Palliat Med; 2020 Sep; 9(5):2943-2952. PubMed ID: 32819122
[TBL] [Abstract][Full Text] [Related]
2. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer.
He L; Li Y; Huang X; Cheng H; Ke Y; Wang L
Onco Targets Ther; 2019; 12():5897-5906. PubMed ID: 31413587
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic significance of SHP2 and Hook1 expression in patients with thyroid carcinoma.
Cao J; Huang YQ; Jiao-Sun ; Lan XB; Ge MH
Hum Pathol; 2018 Nov; 81():105-112. PubMed ID: 29953894
[TBL] [Abstract][Full Text] [Related]
5. SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.
Li S; Wang L; Zhao Q; Liu Y; He L; Xu Q; Sun X; Teng L; Cheng H; Ke Y
J Biol Chem; 2014 Dec; 289(49):34152-60. PubMed ID: 25331952
[TBL] [Abstract][Full Text] [Related]
6. Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).
Karachaliou N; Cardona AF; Bracht JWP; Aldeguer E; Drozdowskyj A; Fernandez-Bruno M; Chaib I; Berenguer J; Santarpia M; Ito M; Codony-Servat J; Rosell R
EBioMedicine; 2019 Jan; 39():207-214. PubMed ID: 30473379
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Liu L; Zhou F; Ren S; Chen X; Li X; Li W; Zhou C
Asia Pac J Clin Oncol; 2016 Jun; 12(2):e339-46. PubMed ID: 25131817
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
[TBL] [Abstract][Full Text] [Related]
11. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Yan D; Wei P; An G; Chen W
J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y
World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534
[TBL] [Abstract][Full Text] [Related]
13. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Ren S; Zhou S; Wu F; Zhang L; Li X; Zhang J; Xu J; Lv M; Zhang J; Zhou C
Lung Cancer; 2012 Jan; 75(1):102-9. PubMed ID: 21676483
[TBL] [Abstract][Full Text] [Related]
14. Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.
Karampeazis A; Vamvakas L; Kentepozidis N; Polyzos A; Chandrinos V; Rigas G; Christofyllakis C; Kotsakis A; Hatzidaki D; Pallis AG; Georgoulias V
Clin Lung Cancer; 2016 Nov; 17(6):543-549. PubMed ID: 27397849
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Natukula K; Jamil K; Pingali UR; Suresh Attili VS; Naidu Madireddy UR
Asian Pac J Cancer Prev; 2013; 14(8):4661-6. PubMed ID: 24083721
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
17. Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
Trani L; Myerson J; Ashley S; Young K; Sheri A; Hubner R; Puglisi M; Popat S; O'Brien ME
Lung Cancer; 2010 Nov; 70(2):200-4. PubMed ID: 20227784
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Ramirez JL; Rosell R; Taron M; Sanchez-Ronco M; Alberola V; de Las Peñas R; Sanchez JM; Moran T; Camps C; Massuti B; Sanchez JJ; Salazar F; Catot S;
J Clin Oncol; 2005 Dec; 23(36):9105-12. PubMed ID: 16361617
[TBL] [Abstract][Full Text] [Related]
19. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK;
Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
